Internal and Emergency Medicine

, Volume 9, Issue 5, pp 559–567 | Cite as

A prospective study on survival in cancer patients with and without venous thromboembolism

  • Giancarlo Agnelli
  • Melina Verso
  • Mario Mandalà
  • Silvano Gallus
  • Claudio Cimminiello
  • Giovanni Apolone
  • Giovanni Di Minno
  • Evaristo Maiello
  • Paolo Prandoni
  • Armando Santoro
  • Lucio Crinò
  • Roberto Labianca
IM - ORIGINAL

Abstract

Retrospective population-based studies showed that in cancer patients venous thromboembolism (VTE) is associated with reduced survival. Master Oncology is a multicenter study in patients with solid advanced cancer aimed at assessing (1) risk factors for VTE using a case–control design, and (2) survival in cases (patients with VTE) and controls (patients without VTE). Survival data were prospectively collected for at least 10 months. Overall, 237 cases and 339 controls were included in the analysis. The following factors were found to be associated with an increased risk of VTE: body mass index (BMI; OR 2.02; 95 % CI 1.31–3.12 for ≥26 vs. <23 kg/m2), ECOG score (OR 2.14; 95 % CI 1.47–3.11 for grade 1, and 3.32; 95 % CI 1.64–6.00 for grade 2–3, compared to grade 0) and recent diagnosis of cancer (OR 1.90; 95 % CI 1.33–2.71 for <12 vs. ≥12 months). After an average prospective observation of 8.3 months, 136 cases (57.4 %) and 127 controls (37.5 %) died with a median survival of 8.7 (95 % CI 7.5–10.9) and 14.3 months (95 % CI 12.2–18.7), respectively, (Wilcoxon = 27.72, p < 0.001; multivariate hazard ratio 1.55; 95 % CI 1.21–2.00). Median survival time was reduced for both patients with symptomatic (Wilcoxon = 35.22, p < 0.001) and asymptomatic VTE (Wilcoxon = 4.63, p = 0.031). Patients with advanced solid cancer, high BMI, high ECOG score, and recent diagnosis of cancer are associated with an increased risk for VTE. Patients with both symptomatic and asymptomatic VTE have a reduced survival compared to those without VTE.

Keywords

Venous thromboembolism Cancer Deep venous thrombosis Pulmonary embolism Survival 

References

  1. 1.
    Sorensen ET, Mellemkjaer L, Olsen JH et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850PubMedCrossRefGoogle Scholar
  2. 2.
    Falciani M, Imberti D, Prisco D (2006) Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update. Intern Emerg Med 1(4):273–278PubMedCrossRefGoogle Scholar
  3. 3.
    Wun T, White RH (2009) Venous thromboembolism in patients with cancer: epidemiology and risk factors. Cancer Invest 27(Suppl 1):63–74PubMedCrossRefGoogle Scholar
  4. 4.
    Verso M, Agnelli G, Barni S et al (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 130(3):369–373Google Scholar
  5. 5.
    Alcalay A, Wun T, Khatri V et al (2006) Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 24:1112–1118PubMedCrossRefGoogle Scholar
  6. 6.
    Chew HK, Davies AM, Wun T (2008) The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 6:601–608PubMedCrossRefGoogle Scholar
  7. 7.
    Chew HK, Wun T, Harvey D et al (2006) The incidence of venous thromboembolism and its effect on survival among patients with common cancer. Arch Intern Med 166:458–464PubMedCrossRefGoogle Scholar
  8. 8.
    Chew HK, Wun T, Harvey DJ et al (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25:70–76PubMedCrossRefGoogle Scholar
  9. 9.
    Starling N, Rao S, Cunningham D et al (2009) Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 27:3786–3793PubMedCrossRefGoogle Scholar
  10. 10.
    Mandala` M, Reni M, Cascinu S et al (2007) Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 18:1660–1665PubMedCrossRefGoogle Scholar
  11. 11.
    Sandhu R, Pan CX, Wun T et al (2010) The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer 116:2596–2603PubMedGoogle Scholar
  12. 12.
    Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMedCrossRefGoogle Scholar
  13. 13.
    Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume I: the analysis of case-control studies. IARC Sci Publ 32:5–338PubMedGoogle Scholar
  14. 14.
    Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C (1985) Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 122:904–914PubMedGoogle Scholar
  15. 15.
    Benichou J, Gail MH (1990) Variance calculations and confidence intervals for estimates of the attributable risk based on logistic models. Biometrics 46:991–1003PubMedCrossRefGoogle Scholar
  16. 16.
    den Exter PL, Hooijer J, Dekkers OM et al (2011) Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29:2405–2409CrossRefGoogle Scholar
  17. 17.
    Dentali F, Ageno W, Pierfranceschi MG et al (2011) Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost 9:1081–1083PubMedCrossRefGoogle Scholar
  18. 18.
    Sargent DJ, Köhne CH, Sanoff HK et al (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27:1948–1955PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Mandalà M, Barni S, Floriani I et al (2009) Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the ‘GISCAD-alternating schedule’ study findings. Eur J Cancer 45:65–73PubMedCrossRefGoogle Scholar
  20. 20.
    Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2013

Authors and Affiliations

  • Giancarlo Agnelli
    • 1
  • Melina Verso
    • 1
  • Mario Mandalà
    • 2
  • Silvano Gallus
    • 3
  • Claudio Cimminiello
    • 4
  • Giovanni Apolone
    • 5
  • Giovanni Di Minno
    • 6
  • Evaristo Maiello
    • 7
  • Paolo Prandoni
    • 8
  • Armando Santoro
    • 9
  • Lucio Crinò
    • 10
  • Roberto Labianca
    • 2
  1. 1.Internal and Cardiovascular Medicine-Stroke UnitUniversity of PerugiaPerugiaItaly
  2. 2.Medical Oncology UnitOspedali RiunitiBergamoItaly
  3. 3.Department of EpidemiologyIstituto di Ricerche Farmacologiche Mario NegriMilanItaly
  4. 4.Department of Medicine, Vimercate Hospital AziendaOspedaliera di Desio E VimercateVimercateItaly
  5. 5.Direzione Scientifica, Azienda Ospedaliera Arcispedale Santa Maria NuovaIRCCSReggio EmiliaItaly
  6. 6.Department of Clinical and Experimental MedicineFederico II University HospitalNaplesItaly
  7. 7.Oncology Unit, IRCCS Casa Sollievo Della SofferenzaSan Giovanni Rotondo (FG)Italy
  8. 8.Department of Cardiothoracic and Vascular Sciences, Clinica Medica 2University of PaduaPaduaItaly
  9. 9.Humanitas, Cancer CenterRozzano (MI)Italy
  10. 10.Division of Medical Oncology, Santa Maria Della Misericordia HospitalAzienda Ospedaliera di PerugiaPerugiaItaly

Personalised recommendations